This study involves people with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study focuses on tumors that have a specific change in a gene called KRAS G12C mutation. This change in the gene can affect how the cancer grows. The study will test a medication called MK-1084, which will be given either alone or together with another medication called cetuximab. The purpose of the study is to see how well these treatments work in shrinking the tumors and to check how safe they are for people taking them.
During the study, people will receive MK-1084 as tablets. Some people will also receive cetuximab, which is given through a vein. The study will compare how well MK-1084 works by itself compared to when it is given together with cetuximab. The study will measure how many tumors respond to the treatment and whether they get smaller. It will also track how long the treatment keeps working and how long people live. Throughout the study, doctors will carefully watch for any side effects or unwanted reactions to the medications.
The study will look at different types of solid tumors that have the KRAS G12C mutation, but it will not include colorectal cancer. People joining the study will have already tried standard treatments for their cancer that did not work or stopped working. The study will continue for several years to gather information about how well the treatments work over time and to ensure the safety of people taking part in the research.
Denmark 
France 
Germany 
Greece 
Italy 
Norway 
Poland 
Spain 
Sweden 